Giammauro Berardi, Federico Tomassini, Roberto Ivan Troisi – 30 March 2015 – Living donor liver transplantation is a valid alternative to deceased donor liver transplantation, and its safety and feasibility have been well determined. Minimally invasive living donor hepatectomy (MILDH) has taken some time to be accepted because of inherent technical difficulties and the highly demanding surgical skills needed to perform the procedure, and its role is still being debated.

Laia Tolosa, Silvia López, Eugenia Pareja, María Teresa Donato, Anne Myara, Tuan Huy Nguyen, José Vicente Castell, María José Gómez‐Lechón – 30 March 2015 – Crigler‐Najjar type 1 disease is a rare inherited metabolic disease characterized by high levels of unconjugated bilirubin due to the complete absence of hepatic uridine diphosphoglucuronate–glucuronosyltransferase activity. Hepatocyte transplantation (HT) has been proposed as an alternative treatment for Crigler‐Najjar syndrome, but it is still limited by the quality and the low engraftment and repopulation ability of the cells used.

Julio A. Gutierrez, Andres F. Carrion, Danny Avalos, Christopher O'Brien, Paul Martin, Kalyan Ram Bhamidimarri, Adam Peyton – 30 March 2015 – Recurrent hepatitis C virus (HCV) infection occurs universally in the allograft in the absence of effective antiviral therapy before liver transplantation (LT). Antiviral therapy with sofosbuvir and simeprevir has proven to be highly effective and well tolerated in the nontransplant setting for treatment of HCV genotype 1 infection; therefore, we sought to evaluate the efficacy and safety of this regimen in LT recipients with recurrent HCV infection.

Weiliang Xia, Qinghong Ke, Ye Wang, Xiaowen Feng, Haijun Guo, Weilin Wang, Min Zhang, Yan Shen, Jian Wu, Xiao Xu, Sheng Yan, Shusen Zheng – 30 March 2015 – Donation after cardiac death (DCD) liver grafts are associated with inferior clinical outcomes and high discard rates because of poor graft quality. We investigated the predictive value of DCD liver biopsy for the pretransplant graft quality evaluation. DCD liver transplants that took place between October 2010 and April 2014 were included (n = 127).

John G. O'Grady – 30 March 2015

Kelly M. Collins, William C. Chapman – 30 March 2015

Giuseppina Basta, Serena Del Turco, Teresa Navarra, William M. Lee, Acute Liver Failure Study Group – 30 March 2015 – Animal studies suggest that receptor for advanced glycation end products (RAGE)–dependent mechanisms contribute to acetaminophen‐induced liver damage.

Nis Hallundbæk Schlesinger, Peter Svenningsen, Susanne Frevert, André Wettergren, Jens Hillingsø – 30 March 2015 – Bile duct stones and casts (BDSs) contribute importantly to morbidity after liver transplantation (LT). The purpose of this study was to estimate the clinical efficacy, safety, and long‐term results of percutaneous transhepatic cholangioscopic lithotripsy (PTCSL) in transplant recipients and to discuss underlying factors affecting the outcome.

Tommaso Di Maira, Angel Rubin, Lorena Puchades, Victoria Aguilera, Carmen Vinaixa, Maria Garcia, Nicola De Maria, Erica Villa, Rafael Lopez‐Andujar, Fernando San Juan, Eva Montalva, Judith Perez, Martin Prieto, Marina Berenguer – 30 March 2015 – Cardiovascular (CV) events represent major impediments to the long‐term survival of liver transplantation (LT) patients. The aim of this study was to assess whether the Framingham risk score (FRS) at transplantation can predict the development of post‐LT cardiovascular events (CVEs). Patients transplanted between 2006 and 2008 were included.

Rajagopal N. Aravalli, John D. Belcher, Clifford J. Steer – 30 March 2015 – The liver plays a major role in many inherited and acquired genetic disorders. It is also the site for the treatment of certain inborn errors of metabolism that do not directly cause injury to the liver. The advancement of nucleic acid–based therapies for liver maladies has been severely limited because of the myriad untoward side effects and methodological limitations.